Johnson & Johnson stock gains on dividend and guidance as price nears recent high

Published on 09/02/2026 at 10:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock has climbed above 271 dollars as investors focus on the higher dividend and FY 2026 earnings guidance while the shares trade close to their recent highs.

Aquarellbild einer Stadt mit Fluss, Park und modernem Bürocampus — Aquarellmalerei zeigt Stadtansicht am Firmenstandort von Johnson & Johnson, ISIN US4781601046, mit Fluss und Bürogebäuden, Illustration mit AI erstellt.

Johnson & Johnson stock (ISIN US4781601046) has moved higher to around 271.19 dollars as of August 31, 2026, with the latest noted close up about 2.01 percent and near its recent high range according to market data from Zacks and Forbes dated September 1, 2026 and August 31, 2026.

Dividend increase and earnings guidance in focus

According to an analysis by 24/7 Wall St. published on September 1, 2026, Johnson & Johnson reported revenue of 24.06 billion dollars in the first quarter of 2026, underscoring its position as a large diversified healthcare group.

MarketBeat reported on September 1, 2026 that Johnson & Johnson earned 2.90 dollars per share in its latest quarterly release for the second quarter of 2026, beating consensus expectations of 2.84 dollars by 0.06 dollars and generating revenue of 25.31 billion dollars versus 25.06 billion dollars expected, a year over year revenue increase of 6.6 percent and an earnings increase from 2.77 dollars per share in the prior year period.

The same MarketBeat overview highlights that Johnson & Johnson has set full year 2026 earnings guidance in a range of 11.60 to 11.75 dollars per share, while equity analysts currently project about 11.61 dollars per share for the year, offering investors a clear reference point for valuation.

In addition, 24/7 Wall St. notes that Johnson & Johnson lifted its quarterly dividend to 1.34 dollars per share, with an ex dividend date of August 25, 2026 and a payment date of September 8, 2026, corresponding to an annualized dividend of 5.36 dollars per share and yield near 2 percent at recent price levels according to MarketBeat.

Stock performance versus broader market

Data compiled by Zacks on September 1, 2026 shows that Johnson & Johnson shares closed at 271.19 dollars in the latest session, representing a 2.01 percent gain on the day and outperforming the S&P 500, which fell 0.71 percent, as well as declines of 0.79 percent in the Dow and 1.03 percent in the Nasdaq.

The trading overview on Forbes lists a closing price of 265.85 dollars for Johnson & Johnson on August 31, 2026, after a trading range between 265.17 and 267.77 dollars during that session, illustrating that the Zacks referenced 271.19 dollar level stands noticeably above the immediately prior closing level.

Over recent days in late August 2026, Forbes data shows Johnson & Johnson closing at 268.04 dollars on August 28, 265.77 dollars on August 27 and 270.00 dollars on August 26, indicating that the late August and early September prices mostly fluctuate in a corridor between roughly 265 and 273 dollars while staying below the absolute 52 week highs that long term investors monitor.

For investors, the combination of mid single digit revenue growth in the latest quarter, a modest earnings beat and a rising dividend backed by full year guidance in the 11.60 to 11.75 dollar earnings per share range provides a fundamental backdrop for the current price performance.

Go deeper

More on Johnson & Johnson fundamentals and stock

Investors who want to follow Johnson & Johnson stock and corporate disclosures more closely can access additional news, regulatory filings and financial figures via the thematic overview and the company's investor relations page.

Johnson & Johnson articles on ad-hoc-news.de Investor Relations

Pharmaceuticals and medical devices as revenue pillars

Johnson & Johnson generates its revenue across pharmaceuticals, medical technology and consumer health products, with blockbuster prescription medicines, surgical instruments and diagnostics equipment contributing the bulk of sales.

Analyses of the latest quarters emphasize that prescription treatments in areas such as immunology and oncology remain central drivers of revenue growth in 2026, complementing steady income from surgical products and orthopedic devices sold to hospitals and clinics.

For retail investors, the resilient demand for essential medicines and hospital equipment can translate into relatively stable cash flows and support ongoing dividends, although individual drug patent cycles and regulatory decisions still influence segment trajectories.

Share price level and investor perspective

Based on the trading data from Zacks for September 1, 2026 and Forbes for August 31, 2026, Johnson & Johnson stock is trading around 271.19 dollars with a previous close of 265.85 dollars on the New York Stock Exchange, and the company carries a market capitalization of about 97.93 billion dollars on a trailing twelve month basis as listed by Forbes.